Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Accuray and CyberHeart agree to develop non-invasive cardiac ablation tool

Accuray : 30 April, 2007  (New Product)
Accuray has entered into an agreement with CyberHeart that will see CyberHeart use Accuray’s technology to develop a non-invasive method for performing cardiac ablation.
Cardiac ablation is used to destroy a small portion of the heart that is causing abnormal rhythms. Ultimately, the developed technology may have applications in the treatment of atrial fibrillation, a disorder that prevents the heart from beating properly and can cause blood clots and strokes.

Currently cardiac ablation is done during open-heart surgery or as a Catheter based procedure in which a Catheter is inserted into a blood vessel up to the heart and radiofrequency energy is delivered. Cardiac ablation is most often used to create a lesion that that interferes with abnormal cardiac conduction, with the objective of treating cardiac arrhythmias.

CyberHeart is exploring the use of Accuray’s CyberKnife Robotic Radiosurgery System to generate these lesions non-invasively. The CyberKnife System’s intelligent robotics, accuracy and unique tracking capabilities will be used to target the heart’s affected tissue and create an ablation lesion.

“The heart is not an organ that is typically treated with radiation. However CyberHeart believes that by using highly accurate Radiosurgery technology, we can effectively ablate cardiac tissue and potentially create a lesion that can block abnormal cardiac rhythm,” said Patrick Maguire, MD, PhD, president and CEO of CyberHeart. “Accuray’s CyberKnife System is the only technology available today that offers the precision needed to ensure only very specific regions of the heart are treated. We expect to begin initial clinical trials in 12 to18 months and it is our objective to bring the product to market in the next three to four years.”

CyberHeart has received commitments for independent venture capital financing to fund technical and clinical research and development of a cardiac ablation system that incorporates Accuray’s technology. In the event CyberHeart is able to successfully develop and commercialise such a system, under Accuray’s agreement with CyberHeart, Accuray will be the sole supplier of Radiosurgery equipment to CyberHeart and will also be entitled to receive specified payments based on usage of the CyberHeart system.

“Accuray’s unique CyberKnife technology offers an innovative approach to treating tumours anywhere in the body with radiosurgery,” said Euan S Thomson, PhD, president and CEO of Accuray. “By working with CyberHeart, we may be able to facilitate the development of new applications for the use of our Radiosurgery technology to treat other types of medical conditions that affect millions worldwide.”
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo